We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Celgene Corporation | NASDAQ:CELG | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 108.24 | 109.30 | 109.44 | 0 | 01:00:00 |
From May 2019 to May 2024
By Christopher Zinsli
Centrexion Therapeutics Corp., a pain treatment developer founded by the former leaders of Pfizer Inc. and Celgene Corp., on Friday disclosed plans to go public.
The Boston-based company said the proceeds from its planned initial public offering would fund clinical trials of a series of product candidates. The company's most advanced candidate is a potential treatment for knee pain.
Centrexion said it had an accumulated deficit of $125.7 million as of Sept. 30.
Former Pfizer Chief Executive Jeffrey Kindler is CEO of Centrexion, and former Celgene Corp. Chief Executive Sol Barer is the company's chairman.
Centrexion in January announced a $67 million Series D funding round. New Enterprise Associates led that round and is a significant shareholder, according to the company's IPO prospectus. Other significant owners include InterWest Partners and Quan Capital.
The company intends to secure a listing on the Nasdaq under the symbol CNTX. BofA Merrill Lynch, Leerink Partners and Evercore ISI are leading the offering.
(END) Dow Jones Newswires
October 19, 2018 18:48 ET (22:48 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Celgene Chart |
1 Month Celgene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
